繁體
简体中文
繁體中文

Academy ASO 深 滬

已收盤 11-20 16:00:00 美东时间

69.755

-0.725

-1.03%

华盛通華盛通
立即下載
  • 最 高71.73
  • 今 開69.84
  • 成交量 121.91万股
  • 最 低 69.17
  • 昨 收 70.48
  • 總市值 42.95亿
  • 52周最高 73.82
  • 市盈率 靜 12.60
  • 換手率 1.98%
  • 52周最低 41.87
  • 委 比 81.00%
  • 總股本 6157.89万
  • 歷史最高 74.32
  • 量 比 0.77
  • 振 幅 3.63%
  • 歷史最低 9.98
  • 每 手 1
  • 風險率 5.95%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Academy Sports & Outdoors收跌1.03%,成交额8527.24万美元

    11月21日,Academy Sports & Outdoors(ASO)收跌1.03%,报69.75美元,成交额8527.24万美元,市值42.95亿...

    11-21 06:08

  • Medline Inc. announces pricing of secondary offering of Class A common stock

    <p>Medline Inc. announced a secondary offering of 60 million shares of its Class A common stock by certain selling stockholders affiliated with major investors. The shares are priced at $35.50 each, with an option for underwriters to purchase up to an additional 9 million shares. Medline is not participating in the offering and will not receive proceeds from the sale. The offering is expected to close on November 23, 2026. The company also plans ...

    11-18 03:23

  • WRAP Reports 43% Nine-Month Revenue Growth; Highlights Ongoing Congressional, ATF and State Actions Supporting Non-Lethal Response

    Wrap Technologies reported Q3 2026 revenue of $1.5M, up 43% year-over-year for the first nine months, driven by product sales growth. The company raised $12M via a registered direct offering and invested $2M in Frenel Imaging to advance its WrapShield platform. Illinois certified the BolaWrap 150 training course, and ATF classified it as a restraint instrument. The company also appointed new executives and launched Wraptor MX prototype.

    11-16 21:00

  • Academy Sports & Outdoors收跌2.93%,成交额8076.67万美元

    11月13日,Academy Sports &amp; Outdoors(ASO)收跌2.93%,报67.29美元,成交额8076.67万美元,市值41.44亿...

    11-13 06:15

  • NYSE: MMA – MMA.INC’s Verified Network Growth Lifts Illustrative Annual Revenue Opportunity to US$21 Million

    MMA.INC reported significant growth in its BJJLink network, with verified gyms increasing 14.0% to 1,148 and registered students rising 12.4% to 120,048. The company highlighted its potential to expand revenue through software, payments, and training programs, with illustrative annual revenue scenarios of $21 million for the verified network and $180 million for the broader network at hypothetical full adoption. MMA.INC aims to convert more verif...

    11-12 13:45

  • 美股大行评级 | 富国银行维持英伟达"超配"评级!但目标价从315美元降至300美元

    今日重点评级关注:花旗:维持Faeth Therapeutics"买入"评级,目标价从55美元升至60美元;HC Wainwright & Co.:维持Ocular Therapeutix"买入"评级,目标价从25美元升至28美元

    11-11 10:50

  • Wrap Technologies, Inc. to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 at 4:30 p.m. ET

    Wrap Technologies, Inc. (NASDAQ: WRAP) announced it will hold a conference call on Monday, November 16, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its third-quarter 2026 financial and operational results. The call will include a presentation by management followed by a Q&A session. Investors can submit questions by November 12, 2026, at ir@wrap.com. The earnings press release and related materials will be available on the...

    11-09 22:15

  • Apollo Prices Offering of Fixed-Rate Resettable Junior Subordinated Notes

    Apollo Global Management has priced a $600 million offering of 7.550% Fixed-Rate Resettable Junior Subordinated Notes due 2056. The notes will be guaranteed by certain subsidiaries and will bear a fixed rate until December 2036, after which the rate will reset based on the five-year U.S. Treasury rate plus a spread. Proceeds will be used for general corporate purposes, including an investment in Mubadala Capital Asset Management. The offering is ...

    11-09 22:00

  • ImageneBio Reports Third Quarter 2026 Financial Results

    ImageneBio reported financial results for Q3 2026, highlighting progress in its olevaprubart program for atopic dermatitis and alopecia areata. The company has $126.6M in cash and anticipates completing its Phase 2b ADAPTIVE trial by Q4 2027. R&D expenses were $11.3M, down from $15.2M in Q3 2025, with a net loss of $15.6M. Olevaprubart continues to show promise with no observed safety concerns, and Imagene plans to initiate a Phase 2 study for al...

    11-09 21:05

  • Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology

    Kyverna Therapeutics announced the publication of its KYSA-8 trial data in *JAMA Neurology*, highlighting miv-cel's potential as the first approved therapy for stiff person syndrome (SPS) and the first CAR T-cell therapy for autoimmune diseases. The study showed statistically significant improvements in mobility and disability after a single dose, with patients no longer needing chronic immunotherapies. Miv-cel demonstrated a well-tolerated safet...

    11-09 16:00